BOSTON, April 25, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 11, 2023.
The call can be accessed via teleconference at: Q4 2023 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/wm7hxoqy
A replay of the conference call and webcast will be available for one year beginning on May 11, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts:
Olga Guyette, Sr. Director-Investor Relations & Treasury
(781) 356-9763
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Trenk, Manager-Investor Relations
(203) 733-4987
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$72.55 |
| Daily Change: | -0.90 -1.23 |
| Daily Volume: | 726,294 |
| Market Cap: | US$3.490B |
May 08, 2025 February 24, 2025 February 06, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
